Clinical Trials Browser

Phase 1/2 × OTHER × Capecitabine × Clear all

NCT06134375 2026-03-12

A Study of Tetrathiomolybdate (TM) Plus Capecitabine

Phase 1/2 Recruiting

Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT04333706 2026-03-10

EMPOWER

Phase 1/2 Recruiting

Neoplasm Metastasis, Neoplasms

NCT06374459 2026-02-09

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

Phase 1/2 Recruiting

Breast Neoplasms

NCT07365592 2026-01-26

Neo-CD

Phase 1/2 Not yet recruiting

Gastrointestinal

Colorectal Neoplasms

NCT04564898 2026-01-08

TriComB

Phase 1/2 Active not recruiting

Gastrointestinal

Colorectal Cancer Metastatic

NCT04711824 2025-12-23

SOLARA

Phase 1/2 Recruiting

Brain Neoplasms, Breast Neoplasms

NCT05990543 2025-09-08

Combination of Nelmastobart and Capecitabine Therapy in Metastatic Colorectal Cancer

Phase 1/2 Active not recruiting

Gastrointestinal

Recurrence, Colorectal Neoplasms

NCT04031872 2025-09-05

LY3200882 and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer (EORTC1615)

Phase 1/2 Withdrawn

Gastrointestinal

Colorectal Cancer Metastatic

NCT04963088 2025-06-26

TALENT

Phase 1/2 Completed

Gastrointestinal

Stomach Neoplasms

NCT01349088 2025-05-02

Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer

Phase 1/2 Withdrawn

Breast Neoplasms

NCT05535413 2025-04-25

UTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases

Phase 1/2 Recruiting

Brain Neoplasms

NCT03377387 2025-04-15

Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT03213002 2025-04-09

CAPTEM

Phase 1/2 Recruiting

Brain Neoplasms, Glioblastoma, Neoplasms

NCT06888674 2025-03-21

Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer.

Phase 1/2 Not yet recruiting

Gastrointestinal

Pancreatic Cancer Resectable

NCT02734290 2025-03-10

Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer

Phase 1/2 Active not recruiting

29 enrolled 12 charts

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT03535727 2024-12-31

A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer

Phase 1/2 Completed

48 enrolled 24 charts

Gastrointestinal

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Neoplasms, Neoplasms, Glandular and Epithelial, Pancreatic Diseases, Pancreatic Neoplasms

NCT06139211 2024-12-20

A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Advanced Solid Tumor

NCT02861300 2024-12-19

CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer

Phase 1/2 Completed

50 enrolled 16 charts

Gastrointestinal

Colonic Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Rectal Neoplasms, Colorectal Neoplasms

NCT04940546 2024-12-03

Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in PMMR/MSS CRLM Patients

Phase 1/2 Active not recruiting

Gastrointestinal

Colorectal Cancer Metastatic

NCT02024009 2024-07-25

SCALOP-2

Phase 1/2 Completed

Gastrointestinal

Pancreatic Neoplasms

NCT02735239 2024-03-22

Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer

Phase 1/2 Completed

73 enrolled 18 charts

Gastrointestinal

Adenocarcinoma Of Esophagus, Diabetes Mellitus, Insulin-Dependent, 12, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT03853707 2024-02-20

Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer

Phase 1/2 Completed

28 enrolled 12 charts

Triple Negative Breast Neoplasms

NCT03376659 2024-02-05

Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma

Phase 1/2 Terminated

8 enrolled 14 charts

Gastrointestinal

Pancreatic Neoplasms, Colorectal Neoplasms

NCT06195670 2024-01-08

Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC

Phase 1/2 Not yet recruiting

Gastrointestinal

Colorectal Neoplasms

NCT04751955 2023-10-31

A Phase lb/ll, Open Label, Single Arm Study With Olinvacimab and Capecitabine in mCRC Patients (OLCAP)

Phase 1/2 Withdrawn

Gastrointestinal

Colorectal Cancer Metastatic

NCT02324543 2023-07-21

Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer

Phase 1/2 Completed

47 enrolled 22 charts

Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

NCT04522284 2023-03-29

PRECISE CURATE.AI Pilot Clinical Trial

Phase 1/2 Unknown

Waldenstrom Macroglobulinemia, Neoplasms

NCT01898104 2023-03-24

V-shoRT-R3

Phase 1/2 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT04782804 2022-08-18

Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence

Phase 1/2 Unknown

Gastrointestinal

Cholangiocarcinoma

NCT03844256 2022-08-12

CRIMI

Phase 1/2 Recruiting

Urinary Bladder Neoplasms

NCT03805399 2022-08-10

FUTURE

Phase 1/2 Unknown

Triple Negative Breast Neoplasms

NCT00193128 2021-11-24

Preoperative Therapy With Oxaliplatin/Docetaxel/Capecitabine and Radiation in Resectable Esophagus Cancer

Phase 1/2 Completed

59 enrolled 8 charts

Gastrointestinal

Esophageal Neoplasms

NCT02948348 2021-09-16

Study to Nivolumab Following Preoperative Chemoradiotherapy

Phase 1/2 Unknown

Gastrointestinal

Rectal Neoplasms

NCT02393755 2021-07-08

Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer

Phase 1/2 Completed

42 enrolled 16 charts

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT04943653 2021-07-06

IPXELOX

Phase 1/2 Unknown

Gastrointestinal

Stomach Neoplasms

NCT01077986 2021-04-21

Everolimus, Cetuximab and Capecitabine in Patients With Metastatic Pancreatic Cancer

Phase 1/2 Completed

Gastrointestinal

Pancreatic Neoplasms

NCT02010567 2020-11-03

Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer

Phase 1/2 Terminated

32 enrolled 18 charts

Gastrointestinal

Rectal Neoplasms, Colorectal Neoplasms

NCT01302613 2020-08-20

Altered Chemotherapy Sequencing During Neoadjuvant Therapy for Patients With Stage II or III Rectal Adenocarcinoma

Phase 1/2 Withdrawn

Gastrointestinal

Rectal Neoplasms

NCT04202978 2020-04-16

Camrelizumab Combined With Apatinib 、XELOX 、RFA in the Treatment of Liver Metastases of Colorectal Cancer

Phase 1/2 Unknown

Gastrointestinal

Hepatic Metastasis of Colorectal Cancer

NCT01193517 2020-04-15

Azacitidine and CAPOX in Metastatic Colorectal Cancer

Phase 1/2 Completed

26 enrolled 12 charts

Gastrointestinal

Colorectal Neoplasms

NCT00565370 2020-01-18

Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC): Sorafenib+XP

Phase 1/2 Completed

22 enrolled 11 charts

Gastrointestinal

Stomach Neoplasms

NCT04227041 2020-01-14

A Study of Pyrotinib Combined With Capecitabine for Metastatic HER-2 Positive Colorectal Cancer

Phase 1/2 Unknown

Gastrointestinal

HER-2 Positive Colorectal Cancer

NCT00634751 2019-11-26

CO07204-Phase I/II of Oxaliplatin, Capecitabine & Sorafenib for Advanced Pancreatic & Biliary Carcinoma

Phase 1/2 Completed

48 enrolled 13 charts

Gastrointestinal

Bile Duct Neoplasms, Pancreatic Neoplasms

NCT01783756 2019-11-12

Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis

Phase 1/2 Completed

Breast Neoplasms, Breast Neoplasms, Male

NCT02773459 2019-09-30

MEK162 in Combination With Capecitabine in Advanced Biliary Tract Cancer

Phase 1/2 Completed

Gastrointestinal

Biliary Tract Neoplasms

NCT02352831 2019-08-28

Tosedostat With Capecitabine in Patients With Metastatic Pancreatic Adenocarcinoma

Phase 1/2 Terminated

16 enrolled 15 charts

Gastrointestinal

Pancreatic Neoplasms

NCT03470350 2019-07-24

EORTC1615

Phase 1/2 Withdrawn

Gastrointestinal

Colorectal Cancer Metastatic

NCT04008511 2019-07-05

Regorafenib and XELOX as 2nd Line Treatment in Metastatic Colorectal Cancer

Phase 1/2 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT00004187 2019-06-26

Capecitabine and Oxaliplatin in Treating Patients With Advanced or Metastatic Colorectal Cancer

Phase 1/2 Completed

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00869570 2019-05-15

External-Beam Radiation Therapy, Capecitabine, and Sorafenib in Treating Patients With Locally Advanced Rectal Cancer

Phase 1/2 Completed

Gastrointestinal

Rectal Neoplasms, Colorectal Neoplasms